Cellectis S.A. (EPA:ALCLS)
3.570
+0.022 (0.62%)
May 14, 2026, 5:35 PM CET
Cellectis Revenue
Cellectis had revenue of $7.55M USD in the quarter ending March 31, 2026, a decrease of -37.25%. This brings the company's revenue in the last twelve months to $75.11M, up 37.20% year-over-year. In the year 2025, Cellectis had annual revenue of $79.59M with 61.72% growth.
Revenue (ttm)
$75.11M
Revenue Growth
+37.20%
P/S Ratio
3.95
Revenue / Employee
$328.00K
Employees
229
Market Cap
257.55M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.59M | 30.38M | 61.72% |
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 174.66M |
| Genfit | 65.43M |
| MedinCell | 32.44M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Sensorion | 5.81M |
| MaaT Pharma | 4.52M |
| ABIONYX Pharma | 4.10M |
Cellectis News
- 1 day ago - Cellectis (CLLS) Announces Clinical Trial Presentations at EHA Congress - GuruFocus
- 1 day ago - Cellectis to present clinical data on lasme-cel, eti-cel at EHA Congress - TheFly
- 2 days ago - Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress - GlobeNewsWire
- 2 days ago - Cellectis (CLLS) Reports Strong Cash Position for Future Operations - GuruFocus
- 2 days ago - Cellectis (CLLS) Reports Q1 Revenue and Highlights Future Developments - GuruFocus
- 2 days ago - Cellectis reports Q1 adjusted EPS (16c) vs. (17c) last year - TheFly
- 2 days ago - Cellectis sees cash runway into 4Q27 - TheFly
- 2 days ago - Cellectis Reports Financial Results for the First Quarter 2026 - GlobeNewsWire